United Therapeutics (UTHR) Misses Q3 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
United Therapeutics Corp. (UTHR) PT Raised to $344 at Ladenburg Thalmann
October 31, 2024 7:04 AM EDTLadenburg Thalmann analyst Matthew Kaplan raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $344.00 (from $319.00) while maintaining a Neutral rating.
The analyst comments "3Q24 results. Total revenues for 3Q24 were $748.9 million, higher than our estimate of $746.5 million. The revenue increase in 3Q24 ($748.9... More
